US 7,459,151 B2
	Phosphate-binding polymers for oral administration
Stephen Randall Holmes-Farley, Arlington, Mass. (US); W. Harry Mandeville, III, Lynnfield, Mass. (US); and George M. Whitesides, Newton, Mass. (US)
Assigned to Genzyme Corporation, Cambridge, Mass. (US)
Filed on Dec. 06, 2005, as Appl. No. 11/295,159.
Application 08/929784 is a division of application No. 08/471747, filed on Jun. 06, 1995, granted, now 5,667,775.
Application 11/295159 is a continuation of application No. 10/766638, filed on Jan. 28, 2004, granted, now 7,014,846.
Application 10/766638 is a continuation of application No. 10/322904, filed on Dec. 17, 2002, granted, now 6,858,203.
Application 10/322904 is a continuation of application No. 09/542329, filed on Apr. 04, 2000, granted, now 6,509,013.
Application 09/542329 is a continuation of application No. 08/929784, filed on Sep. 15, 1997, granted, now 6,083,495.
Application 08/471747 is a continuation in part of application No. 08/238458, filed on May 05, 1994, granted, now 5,496,545.
Application 08/238458 is a continuation in part of application No. 08/105591, filed on Aug. 11, 1993, abandoned.
Prior Publication US 2006/0171916 A1, Aug. 03, 2006
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/74 (2006.01); A61K 31/785 (2006.01)

U.S. Cl. 424—78.11  [424/78.1; 424/78.12; 424/78.08; 424/78.16]

20 Claims

1. A method for removing phosphate from a patient in need thereof comprising orally administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising a crosslinked, water insoluble polyallylamine copolymer wherein said crosslinked, water insoluble polyallylamine copolymer consists of a crosslinking agent and repeat units represented by the following structural formulae: wherein n is an integer, and X− represents a negatively charged counterion.